This page shows the latest PARP inihibitor news and features for those working in and with pharma, biotech and healthcare.
Fourth to market aims to carve out niche. EU regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with BRCA-mutated breast cancer, opening up another front in a ... Meanwhile, Pfizer’s drug will also have to compete with two
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...